Overview: Bone Marrow Examination 1 Panel
Introduction: The Bone Marrow Examination 1 Panel is a diagnostic tool designed to evaluate bone marrow function using bone marrow samples. In India, hematological disorders (anemias, leukemias, myelodysplastic syndromes) are common (anemia prevalence ~50-70 percent in women/children, leukemia incidence rising), with bone marrow aspiration/biopsy essential for diagnosis. High morbidity from underdiagnosis in rural areas, limited hematology labs, delayed treatment leading to complications or death. Per hematology practices aligned with ICMR guidelines, the test employs microscopy and automated counter for cell count, differential, myeloid/erythroid ratio, and morphology over 1-2 days with high accuracy, valuable for diagnosing marrow disorders. This diagnostic falls under bone marrow screening and targets patients with unexplained cytopenias or hematological suspicion, addressing accurate evaluation to guide therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing mortality. Its bone marrow-based approach ensures reliable detection.
Other Names: BM Exam Pnl 1.
FDA Status: FDA approved, CLIA certified for hematology, compliant with 2025 standards.
Historical Milestone: Standard marrow procedure; in India, essential in hematology centers.
Purpose: The test evaluates 32 parameters including total cell count to guide bone marrow function assessment, diagnose hematological disorders.
Test Parameters: 1. Total Cell Count, 2. Differential Count, 3. Myeloid/Erythroid Ratio, 4-32. Morphology and Cytology Parameters.
Pretest Condition: No fasting required; patients should report fatigue, bleeding, infections, or anemia.
Specimen: 1 mL bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 24 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred).
Medical History: Patients should provide details on anemia, bleeding, infections, family hematological history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated disorders including progression, benefits of evaluation, and discomfort from aspiration.
Procedural Considerations: The test involves sample processing using microscopy and automated counter by trained personnel to ensure sterile technique and interpret results within 1-2 days. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low sample volume can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal morphology/count indicates marrow disorder, necessitating specialist input. Normal may require follow-up if suspicion persists.
Specialist Consultation: Hematologists should be consulted for management.
Additional Supporting Tests: Flow cytometry, cytogenetics for confirmation.
Test Limitations: May miss focal lesions; comprehensive approach required.
References: Indian Journal of Hematology 2024, Bone Marrow Studies India 2023.
